# Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

> **NCT05201404** · PHASE3 · RECRUITING · sponsor: **Can-Fite BioPharma** · enrollment: 471 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Cirrhosis

## Interventions

- **DRUG:** Namodenoson
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05201404
- **Lead sponsor:** Can-Fite BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-15
- **Primary completion:** 2026-02
- **Final completion:** 2026-10
- **Target enrollment:** 471 (ESTIMATED)
- **Last updated:** 2025-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05201404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05201404, "Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05201404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*